Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

APTO-253

 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
APTO-253 is a clinical stage small molecule that acts in part by down-regulation of MYC at mRNA and protein levels. MYC onco… Expand
Is this relevant?
2018
2018
APTO-253 is a phase I clinical stage small molecule that selectively induces CDKN1A (p21), promotes G0–G1 cell-cycle arrest, and… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2018
2018
APTO-253 is a small molecule with antiproliferative activity against cell lines derived from a wide range of human malignancies… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2017
2017
KLF4 is a transcriptional factor that can function either as a tumor suppressor or oncogene in cancer based on its cellular… Expand
Is this relevant?
2017
2017
APTO-253 is a Phase 1 clinical stage small molecule that selectively kills acute myeloid leukemia (AML) cells in the absence of… Expand
Is this relevant?
2016
2016
APTO-253 is a small molecule indolyl-phenanthroline-imidazole that exerts potent cytotoxicity against human acute myeloid… Expand
Is this relevant?
2015
2015
SummaryIntroduction This phase I, multicenter, open-label, single-arm, dose-escalation study evaluated the safety… Expand
  • table 1
  • table 3
Is this relevant?
2014
2014
APTO-253, a small molecule that mediates anticancer activity through induction of the Kruppel-like factor 4 (KLF4) tumor… Expand
Is this relevant?